 |
| Maria Raquel Cochez (Wikimedia Commons) |
Last Friday, the U.S. Food & Drug Administration
approved the use of lisdexamfetamine dimesylate for treatment of binge-eating disorder. Licensed under the brand name
Vyvanse, lisdexamfetamine is the first and only FDA-approved medication for this condition.
But Vyvanse has already been on the market since 2007 for once-daily usage in attention deficit hyperactivity disorder (ADHD) in children and adults.
How does this drug act on two seemingly distinct conditions?
